Holen Sie sich die Stockscreener-App
9.51
0.31%
-0.03
Vorhandelsmarkt:
9.45
-0.06
-0.63%
Schlusskurs vom Vortag:
$9.54
Offen:
$9.04
24-Stunden-Volumen:
2.39M
Relative Volume:
1.39
Marktkapitalisierung:
$533.84M
Einnahmen:
$27.46M
Nettoeinkommen (Verlust:
$-46.05M
KGV:
-7.3721
EPS:
-1.29
Netto-Cashflow:
$-33.83M
1W Leistung:
+17.26%
1M Leistung:
+4.85%
6M Leistung:
+26.97%
1J Leistung:
+37.03%
1-Tages-Spanne:
$8.94
$9.51
1-Wochen-Bereich:
$8.065
$10.22
52-Wochen-Spanne:
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Firmenname
Zevra Therapeutics Inc
Sektor
Branche
Telefon
(321) 939-3416
Adresse
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Vergleichen Sie ZVRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
9.51 | 535.53M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-08 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Eingeleitet | Guggenheim | Buy |
| 2024-09-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-24 | Bestätigt | Maxim Group | Buy |
| 2024-04-02 | Bestätigt | Maxim Group | Buy |
| 2024-03-12 | Eingeleitet | William Blair | Outperform |
| 2023-03-17 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
How to use a screener to detect Zevra Therapeutics Inc. breakoutsInsider Buying & Free Technical Pattern Based Buy Signals - newser.com
Visual trend scoring systems applied to Zevra Therapeutics Inc.July 2025 Earnings & Consistent Growth Equity Picks - newser.com
What drives Zevra Therapeutics Inc stock priceFibonacci Extensions & Rapid Capital Trading Tips - earlytimes.in
How Zevra Therapeutics Inc. (1GDA) stock trades in high volatilityJuly 2025 Drop Watch & Expert Curated Trade Setup Alerts - newser.com
Will Zevra Therapeutics Inc. (1GDA) stock benefit from Fed rate cutsJuly 2025 Intraday Action & Community Trade Idea Sharing - newser.com
Can trapped investors hope for a rebound in Zevra Therapeutics Inc.Earnings Miss & Fast Gain Stock Trading Tips - newser.com
Will Zevra Therapeutics Inc. rebound enough to break evenQuarterly Market Summary & Safe Capital Growth Trade Ideas - newser.com
How institutional ownership impacts Zevra Therapeutics Inc. stock2025 Momentum Check & Weekly Breakout Watchlists - newser.com
Is Zevra Therapeutics Inc. trending in predictive chart modelsWeekly Trade Analysis & Technical Buy Zone Confirmations - newser.com
Can Zevra Therapeutics Inc. (1GDA) stock sustain breakout momentumPortfolio Profit Report & Expert Verified Movement Alerts - newser.com
What drives Zevra Therapeutics Inc 1GDA stock priceEarnings Revision Updates & Fast Profit Trading Strategies - earlytimes.in
Can Zevra Therapeutics (ZVRA) Turn Clinical Momentum Into Sustainable Competitive Advantage? - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Zevra Therapeutics Inc Stock Analysis and ForecastMarket Depth Overview & Top Analyst Picks Available for Free - Early Times
Zevra Therapeutics rises amid takeover speculation - MSN
Zevra Therapeutics (ZVRA) Sees Surge on Takeover Speculation - GuruFocus
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap UpHere's Why - MarketBeat
Zevra Therapeutics Sees Unusually High Options Volume (NASDAQ:ZVRA) - MarketBeat
Zevra Therapeutics rises amid takeover speculation (ZVRA:NASDAQ) - Seeking Alpha
Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Zevra Therapeutics (NASDAQ:ZVRA) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Goldman Sachs Group Inc. Has $1.46 Million Stake in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Tamara A. Favorito Acquires 3,175 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock - MarketBeat
Aug Drivers: Is Zevra Therapeutics Inc in a long term uptrendJuly 2025 Institutional & Stepwise Trade Signal Guides - خودرو بانک
Aug Wrap: Is Zevra Therapeutics Inc. trading at a discount2025 Earnings Impact & Low Drawdown Investment Ideas - خودرو بانک
Bear Alert: Can Zevra Therapeutics Inc stock double in the next year2025 Earnings Surprises & Stock Timing and Entry Methods - خودرو بانک
Aug Shorts: What is Zevra Therapeutics Incs market positionEarnings Growth Summary & Long-Term Capital Growth Strategies - خودرو بانک
Zevra Therapeutics (NASDAQ:ZVRA) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Zevra Therapeutics Announces Upcoming Oral Presentation at - GlobeNewswire
Support Test: Will Zevra Therapeutics Inc benefit from geopolitical trends2025 Technical Overview & Verified Chart Pattern Trade Signals - خودرو بانک
Short Squeeze: Can Zevra Therapeutics Inc benefit from deglobalization2025 Momentum Check & Verified Swing Trading Watchlists - خودرو بانک
Alvin Shih Adds To Zevra Therapeutics Holding - 富途牛牛
Zevra Therapeutics Announces Presentations on MIPLYFFA® and OLPRUVA® at Upcoming International Conferences - Quiver Quantitative
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sod - GlobeNewswire
First Drug to Stop NPC Disease Progression: Zevra's MIPLYFFA Shows Breakthrough Results in 270 Patients - Stock Titan
Zevra Therapeutics (ZVRA) Announces Positive New Data Supporting Foundational Role of MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C - Yahoo Finance
RSI Check: Is Zevra Therapeutics Inc. in a long term uptrendQuarterly Earnings Summary & AI Driven Price Predictions - خودرو بانک
Insider Buying: Tamara Favorito Acquires Shares of Zevra Therapeutics Inc (ZVRA) - GuruFocus
A Fresh Look at Zevra Therapeutics (ZVRA) Valuation Following New MIPLYFFA Data Release - Yahoo Finance
Alvin Shih At Zevra Therapeutics Tops Up Holding By US$158k - simplywall.st
Published on: 2025-09-16 13:04:37 - khodrobank.com
Woodline Partners LP Raises Holdings in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics gains amid takeover speculation - MSN
Insider Buying: Alvin Shih Acquires 20,000 Shares of Zevra Therapeutics Inc (ZVRA) - GuruFocus
Insider Trends: Can Zevra Therapeutics Inc sustain earnings growth2025 Growth vs Value & Accurate Intraday Trade Tips - خودرو بانک
Stock Report: What is the next catalyst for Zevra Therapeutics IncWeekly Profit Recap & Proven Capital Preservation Methods - خودرو بانک
Insider Trends: What is the next catalyst for Zevra Therapeutics IncSwing Trade & Fast Gaining Stock Strategy Reports - خودرو بانک
Aug Mood: Is Zevra Therapeutics Inc backed by strong institutional buyingJuly 2025 Price Swings & AI Powered Market Entry Strategies - خودرو بانک
Finanzdaten der Zevra Therapeutics Inc-Aktie (ZVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):